Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI

University of British Columbia

$10,000.00

Designing Stem Cell Derived Islets for Diabetes Therapy

FY 2020-21

Summary
Diabetes is a debilitating disorder of high blood sugar that afflicts millions of Canadians. People with type 1 diabetes lack the cells that release the hormone insulin, so multiple daily insulin injections remain the conventional way to control blood sugar levels and survive. Scientists at the University of Alberta made breakthrough improvements to the protocol for transplanting clusters of insulin-producing cells, called 'islets'. The "Edmonton Protocol" procedure is quick and works remarkably well, such that many transplant recipients are able to reduce or even eliminate insulin injections. Unfortunately, the only current source of islets for transplant is recently deceased donors and only a tiny fraction of those in need can receive the procedure. Over the past several years, there have been remarkable breakthroughs in unraveling the process by which islet cells develop naturally in the body. As a result, it is now possible to replicate many steps of this process in the laboratory with cultured stem cells, culminating in insulin producing cells. Exciting clinical trials are now underway in which islet precursor cells generated from cultured stem cells are loaded into thin devices and implanted under the skin. While initial assessments in patients are encouraging, insulin production from the cell containing devices is currently inadequate to reverse diabetes. Our goal is to utilize our broad expertise and a new model of human islet development to significantly improve upon the manufacturing of the islet cells to obtain more robust insulin delivery. To achieve this, we have assembled a diverse team of leading experts from across Canada who will focus their complementary skills towards generating an optimized process to mass produce stem cell derived islet cells that will form the basis for new clinical trials in patients with type 1 diabetes, and ultimately generate an effective therapy that will free Canadians from insulin injections.
Program
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
446707
Name
Kieffer Timothy J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant: Diabetes Mechanisms and Translational Solutions - LOI
Projecttitle
Designing Stem Cell Derived Islets for Diabetes Therapy
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
Keyworddelim
Biomedical Engineering; Bioprocess Engineering; Cell Transplantation; Diabetes; Islets; Pseudoislets; Stem Cells
Abstract
Diabetes is a debilitating disorder of high blood sugar that afflicts millions of Canadians. People with type 1 diabetes lack the cells that release the hormone insulin, so multiple daily insulin injections remain the conventional way to control blood sugar levels and survive. Scientists at the University of Alberta made breakthrough improvements to the protocol for transplanting clusters of insulin-producing cells, called 'islets'. The "Edmonton Protocol" procedure is quick and works remarkably well, such that many transplant recipients are able to reduce or even eliminate insulin injections. Unfortunately, the only current source of islets for transplant is recently deceased donors and only a tiny fraction of those in need can receive the procedure. Over the past several years, there have been remarkable breakthroughs in unraveling the process by which islet cells develop naturally in the body. As a result, it is now possible to replicate many steps of this process in the laboratory with cultured stem cells, culminating in insulin producing cells. Exciting clinical trials are now underway in which islet precursor cells generated from cultured stem cells are loaded into thin devices and implanted under the skin. While initial assessments in patients are encouraging, insulin production from the cell containing devices is currently inadequate to reverse diabetes. Our goal is to utilize our broad expertise and a new model of human islet development to significantly improve upon the manufacturing of the islet cells to obtain more robust insulin delivery. To achieve this, we have assembled a diverse team of leading experts from across Canada who will focus their complementary skills towards generating an optimized process to mass produce stem cell derived islet cells that will form the basis for new clinical trials in patients with type 1 diabetes, and ultimately generate an effective therapy that will free Canadians from insulin injections.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kieffer, Timothy J; Hoesli, Corinne; Rideout, Elizabeth J; Shakiba, Nika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $10,000~ $0~